Results
|
|
1.
|
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. MedStar authors:
Year: 2016
Citation: - Cancer Epidemiology, Biomarkers & Prevention. 25(1):51-9, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
All authors: - Anderson SJ, Cecchini RS, Costantino JP, Geyer CE Jr, Jeong JH, Lembersky BC, Paterson AH, Rastogi P, Romond EH, Swain SM, Tang G, Wolmark N
|
|
|
2.
|
The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. MedStar authors:
Year: 2016
Citation: - Breast Cancer Research & Treatment. 155(2):235-51, 2016 Jan.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Amiri-Kordestani L, Chavez KJ, Conway CM, Dine JL, Greer YE, Hewitt SM, Lipkowitz S, Merchant AS, O'Sullivan CC, Sinclair S, Steinberg SM, Stone B, Swain SM, Voeller D
|
|
|
3.
|
SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. MedStar authors:
Year: 2019
Citation: - Journal of Translational Medicine. 17(1):429, 2019 12 26.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Baste N, Clayburgh D, Cohen EEW, Fountzilas G, Fujii T, Khaliq A, Kim ES, Lin D, Lipworth L, Mehlhorn H, Melillo G, Pai SI, Resteghini C, Shara N, Shire N, Stokes M, Twumasi-Ankrah P, Wang H, Wildsmith S, Zhang J
|
|
|
4.
|
Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab. MedStar authors:
Year: 2020
Citation: - Clinical Cancer Research. 26(6):1258-1266, 2020 03 15.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Attia S, Bolejack V, Burgess M, Davis LE, Hu J, Keung EZ, Lazar AJ, Movva S, Okuno S, Parra Cuentas E, Priebat DA, Reed DR, Reinke DK, Reuben A, Riedel RF, Rodrigues-Canales J, Roland CL, Salazar R, Schuetze SM, Tawbi HA, Van Tine BA, Wang WL, Wargo JA
|
|
|
5.
|
Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC. MedStar authors:
- Atkins, Michael
- Fishbein, Thomas M
- Satoskar, Rohit
Year: 2016
Citation: - Cancer Immunology Research. 4(5):419-30, 2016 May
Institution:
- MedStar Washington Hospital Center
- Washington Cancer Institute
Department:
- Georgetown Transplant Institute
- Surgery/Transplantation
Medline publication type:
All authors: - Atkins M, Banovac F, Feng P, Fishbein T, Gabrielson A, Gatalica Z, He AR, Island E, Jha R, Jiang J, Johnson L, Kachhela J, Kallakury B, Kleiner D, Loffredo C, Marshall J, Prins P, Reddy S, Satoskar R, Tesfaye A, Wang H, Weiner L, Wu Y, Zhang T
|
|
|
6.
|
Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5. MedStar authors:
Year: 2017
Citation: - Clinical Breast Cancer. 17(1):48-54.e3, 2017 Feb
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Ansari B, Buyse ME, Conlin AK, Geyer CE Jr, Gross HM, Jacobs SA, Keogh GP, Lord RS, Mamounas EP, Mauquoi C, Patocskai EJ, Polikoff JA, Rastogi P, Robidoux A, Smith JW 2nd, Stella PJ, Swain SM, Wolmark N
|
